Junshi Biosciences Announces FDA Expanded Emergency Use
First and only neutralizing antibody therapy for this age group...
Stay updated with breaking news from Ir Team. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
First and only neutralizing antibody therapy for this age group...
Investegate announcements from Junshi Biosciences, Junshi Biosciences Announces FDA Expanded Emergency Use Authorization for Etesevimab and Bamlanivimab Administered Together to Include Individuals under the Age of 12
First and only neutralizing antibody therapy for this age groupSHANGHAI, China, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical
--the only anti-PD-1 monoclonal antibody in the NRDL for melanoma and nasopharyngeal carcinomaSHANGHAI, China, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading
SHANGHAI, China, Dec. 03, 2021 -- Junshi Biosciences , a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel...